Cabozantinib significantly improves progression free survival compared to sunitinib as first-line treatment for advanced kidney cancer
Review by a blinded independent radiology review committee (IRC) has [...]
Initiation of phase Ib clinical trial of cabozantinib plus atezolizumab for advanced/metastatic solid tumours
Exelixis announced today the start of a phase 1b clinical trial [...]
Nivolumab and cabozantinib accepted for use within NHS Scotland for advanced kidney cancer
The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, [...]
Cabozantinib for advanced kidney cancer rejected for the second time by NICE
Unfortunately, the National Institute for Health and Care Excellence (NICE) [...]
Advances in kidney cancer drug treatments shake up drug choices
The following article provides a comprehensive summary of the changing [...]
Patient selection is key for kidney cancer treatments
There are now a number of treatment options available for [...]
Cabozantinib plus nivolumab phase 3 clinical trial in first-line kidney cancer
Exelixis and Bristol-Myers Squibb (BMS) have announced a clinical development [...]
Cabozantinib NOT recommended by NICE for advanced kidney cancer
We are disappointed to learn that the National Institute for [...]
Cabozantinib superior to sunitinib as a first-line therapy for advanced kidney cancer
Results from the phase II CABOSUN clinical trial, showing cabozantinib [...]
Exelixis announces phase 1 trial results of cabozantinib plus nivolumab in advanced genitourinary tumours
Exelixis today announced results from a phase 1 trial of [...]
